» Articles » PMID: 33241069

Opportunities to Offer Harm Reduction to People Who Inject Drugs During Infectious Disease Encounters: Narrative Review

Overview
Date 2020 Nov 26
PMID 33241069
Citations 15
Authors
Affiliations
Soon will be listed here.
Abstract

Increased rates of overdose (OD) and blood-borne infections have been associated with injection drug use (IDU). This increasing overlap between IDU-related infectious diseases (ID) is a byproduct of the opioid OD crisis, especially with the transition to synthetic opioids with faster onset and shorter duration leading to potentially more frequent injections. ID specialists are uniquely positioned to positively impact the opioid OD crisis by capitalizing on opportunistic moments of engagement during clinical encounters with people who inject drugs (PWID). Harm reduction services should therefore be expanded and offered to PWID in ID settings to reduce rates of OD, infection, and hospitalization. Major target areas include (1) teaching and distribution of materials related to safer injection practice such as sterile injection supplies, fentanyl test strips, and naloxone; (2) increased screening and access to pre-exposure prophylaxis and postexposure prophylaxis; and (3) initiation of medications for opioid use disorder. Incorporating these strategies in various treatment settings can expand treatment access, improve patient outcomes, and reduce stigma associated with IDU.

Citing Articles

Fentanyl and xylazine crisis: Crafting coherent strategies for opioid overdose prevention.

Jain L, Kaur J, Ayub S, Ansari D, Ahmed R, Dada A World J Psychiatry. 2024; 14(6):760-766.

PMID: 38984339 PMC: 11230091. DOI: 10.5498/wjp.v14.i6.760.


Hospitalization is a missed opportunity for HIV screening, pre-exposure prophylaxis, and treatment.

Bradford W, Akselrod H, Bassler J, Gagnon K, Burkholder G, Carpenter J Addict Sci Clin Pract. 2024; 19(1):22.

PMID: 38528590 PMC: 10964564. DOI: 10.1186/s13722-024-00451-z.


Implementing harm reduction kits in an office-based addiction treatment program.

Shang M, Thiel B, Liebschutz J, Kraemer K, Freund A, Jawa R Harm Reduct J. 2023; 20(1):163.

PMID: 37919741 PMC: 10621216. DOI: 10.1186/s12954-023-00897-5.


Chronic Hepatitis C Virus Infection: An Ongoing Challenge in Screening and Treatment.

Tsai W, Chiang H, Chiu Y, Chien S, Cheng P, Chiu H Life (Basel). 2023; 13(10).

PMID: 37895346 PMC: 10608250. DOI: 10.3390/life13101964.


Harm Reduction: A Missing Piece to the Holistic Care of Patients Who Inject Drugs.

Nolan N, Fracasso Francis S, Marks L, Beekmann S, Polgreen P, Liang S Open Forum Infect Dis. 2023; 10(8):ofad402.

PMID: 37593531 PMC: 10428197. DOI: 10.1093/ofid/ofad402.


References
1.
Potier C, Laprevote V, Dubois-Arber F, Cottencin O, Rolland B . Supervised injection services: what has been demonstrated? A systematic literature review. Drug Alcohol Depend. 2014; 145:48-68. DOI: 10.1016/j.drugalcdep.2014.10.012. View

2.
Summers P, Struve I, Wilkes M, Rees V . Injection-site vein loss and soft tissue abscesses associated with black tar heroin injection: A cross-sectional study of two distinct populations in USA. Int J Drug Policy. 2016; 39:21-27. DOI: 10.1016/j.drugpo.2016.08.006. View

3.
Schillie S, Vellozzi C, Reingold A, Harris A, Haber P, Ward J . Prevention of Hepatitis B Virus Infection in the United States: Recommendations of the Advisory Committee on Immunization Practices. MMWR Recomm Rep. 2018; 67(1):1-31. PMC: 5837403. DOI: 10.15585/mmwr.rr6701a1. View

4.
Oh S, Havlen P, Hussain N . A case of polymicrobial endocarditis caused by anaerobic organisms in an injection drug user. J Gen Intern Med. 2005; 20(10):C1-2. PMC: 1490230. DOI: 10.1111/j.1525-1497.2005.0176_1.x. View

5.
Hawk M, Coulter R, Egan J, Fisk S, Friedman M, Tula M . Harm reduction principles for healthcare settings. Harm Reduct J. 2017; 14(1):70. PMC: 5655864. DOI: 10.1186/s12954-017-0196-4. View